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tines after FMT, but no indications for  C. difficile colonization. 
 Conclusions: Metagenomic analysis proved suitable to ana-
lyze the intestinal microbiome after FMT. Discussion of our 
evaluation procedure and data management may be helpful 
for future studies. We demonstrated restoration of a healthy 
and diverse gut microbiome with chimeric composition 
from donor and recipient, and long-lasting clearance of 
 C. difficile . The procedure is simple, cheap, caused no side ef-
fects, and was stable over 3 years.  © 2013 S. Karger AG, Basel 
 Introduction 
 Hospital-acquired infections with  Clostridium diffi-
cile are the most common cause of antibiotic-associated 
diarrhea  [1] . Antibiotic disruption of the intestinal mi-
crobiota followed by colonization with toxin-producing 
 C. difficile spores commonly found in healthcare facili-
ties causes  C. difficile -associated disease (CDAD), which 
in severe cases requires colectomy or leads to death  [1] . 
The emergence of new  C. difficile strains, such as ribo-
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 Abstract 
 Background:  Clostridium difficile infections upon antibiotic 
disruption of the gut microbiota are potentially lethal. Fecal 
microbiota transplantation (FMT) is a promising treatment 
option for recurrent  C. difficile -associated disease (CDAD). 
Here, we present a patient with recurrent CDAD that re-
ceived FMT, leading to full recovery for what has now been 
3 years. We performed metagenomic sequencing on stool 
samples to assess if there are indications for recolonization 
with  C. difficile and changes in the gut microbiota after FMT. 
 Methods: DNA from the stool of the donor and recipient was 
subjected to illumina sequencing. Obtained read sets were 
assembled to contiguous sequences and open reading 
frames were predicted. Deduced proteins were taxonomi-
cally assigned.  Results: We detected complex and apparent-
ly healthy microbiomes in the donor’s and recipient’s intes-
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type 027 (also designated NAP1, BI or toxin type III) 
with increased virulence, toxin expression and antibiotic 
resistance may be responsible for an increase in CDAD 
incidence and death rates during the last years  [2, 3] . In 
addition to the elderly as the main risk group, children, 
young adults and pregnant women are increasingly be-
coming infected  [4–6] . Ribotype 027 has quickly spread 
throughout America, Europe, Asia and Oceania  [7] .
 Current treatment relies on the antibiotics metronida-
zole or vancomycin  [8–10] . However, despite efficient 
antibiotic treatment of individual episodes, about 30% of 
patients suffer from one or more recurrent CDAD epi-
sodes  [11–13] , which has led to the investigation of fecal 
bacteriotherapy, or fecal microbiota transplantation 
(FMT), as an alternative treatment option  [14–37] . 
 The objective of FMT is restoring an intact normal in-
testinal microbiota, which prevents overgrowth by patho-
genic  C. difficile . Donor stool for this kind of treatment is 
usually obtained from a spouse/intimate partner or rela-
tive tested for various pathogens prior to transplantation. 
Anecdotal reports and various smaller case series have 
suggested a high success rate (80–100%) of FMT to treat 
recurrent CDAD  [14–36] . Moreover, the first controlled 
randomized clinical trial has recently reported the supe-
riority of FMT to standard antibiotic therapy  [37] . FMT 
has not been widely implemented in clinical practice un-
til today, likely due to safety concerns and the risk of 
transmitting infectious pathogens from donor to recipi-
ent  [22, 25, 27] . 
 Successful treatment of CDAD by FMT depends on es-
tablishing a normal microbiome in the recipient’s intesti-
nal tract while avoiding transmission of pathogenic micro-
organisms. This requires a reliable means of surveillance 
of the microbiome in the recipient. To address this issue, 
we investigated a metagenomics approach using sequenc-
ing-by-synthesis (illumina sequencing) to obtain insights 
into the microbiome of a CDAD patient who underwent 
successful FMT after antibiotic therapy failed repeatedly. 
Upon FMT, the patient fully recovered and has shown no 
signs of CDAD for what has now been 3 years since FMT. 
 To detect a potential persistent CDAD infection, we 
analyzed the composition of the intestinal microbiome to 
follow the treatment course over time through metage-
nomic deep sequencing. Our approach allowed detection 
of intestinal microorganisms up to the species level. We 
found no evidence for the presence of a  C. difficile infec-
tion in the recipient’s intestinal microbiome, providing 
scientific evidence not only for the clinical efficacy of 
FMT, but also of its potential to successfully eliminate 
potential pathogenic residues of  C. difficile in this patient. 
 Case History 
 A 51-year-old woman was admitted to our hospital with her 
sixth episode of recurrent CDAD. The patient was afebrile and de-
nied weight loss or hematochezia, but suffered from severe diar-
rhea (6–8 times per day) that had reoccurred 2 weeks after cessa-
tion of oral vancomycin. On admission, the patient presented with 
normal vital signs. The abdominal exam revealed a mildly and dif-
fusely tender abdomen without involuntary guarding or rebound 
tenderness.
 Stool samples of this patient tested negative by standard diag-
nostic tests for  Salmonella ,  Shigella ,  Campylobacter ,  Vibrio , 
 Aeromonas and  Plesiomonas spp., enterovirulent  Escherichia coli , 
and intestinal parasites. However, the VIDAS  C. difficile toxin A 
and B immune assay (EIA; BioMérieux, Marcy L’Étoile, France) 
was positive. Selective cultures on cycloserine-cefoxitin-fructose 
agar (BD Difco, Franklin Lakes, N.J., USA) followed by confirma-
tion of suspect colonies with an agglutination assay (Microgen 
 C.  difficile ; Microgen Bioproducts Ltd., Camberley, UK) grew 
 C. difficile . A PCR assay for  C. difficile toxin genes  tcdA and  tcdB 
(Xpert  C. difficile ; Cepheid, Sunnyvale, Calif., USA) was positive as 
well. For antimicrobial susceptibility testing, minimal inhibitory 
concentrations of metronidazole and vancomycin were deter-
mined with the Etest assay (BioMérieux, Marcy L’Étoile, France). 
Minimal inhibitory concentration for rifampicin (Sigma-Aldrich 
GmbH, Zug, Switzerland) as a surrogate for rifaximin was deter-
mined using the microdilution method according to the guidelines 
of the Clinical Laboratory Standards Institute (CLSI)  [38] . Mini-
mal inhibitory concentrations were in the susceptible range with 
0.5  mg/l (vancomycin), 0.25 mg/l (metronidazole) and <0.002 
mg/l (rifampicin).
 The patient’s personal medical history comprised recurrent 
migraine headaches (currently around 2 episodes per month), per-
forated appendicitis with peritonitis (around 30 years before-
hand), repetitive laparoscopic investigations with regard to endo-
metriosis, and cystic lesions of the ovary and hemithyroidectomy 
due to unilateral toxic goiter (requiring thyroid consecutive hor-
mone replacement).
 Two years before the current admission, the patient suffered 
from a complicating jawbone infection requiring 3 surgical de-
bridements. Peroral (p.o.) antibiotic therapy was installed for a 
total of 7 months and the antibiotic regimen was changed several 
times due to insufficient clinical response. Antibiotic therapy was 
started with clindamycin, metronidazole combined with amoxicil-
lin/clavulanic acid and amoxicillin/clavulanic acid alone. Infection 
could finally be cured after 10 weeks of amoxicillin/clavulanic acid. 
In the course of the longstanding antibiotic treatment, the patient 
suffered from the first CDAD episode with severe diarrhea 
9 months before the current hospital admission.
 As an initial treatment, according to the current recommen-
dations  [10] , metronidazole 500 mg p.o. 3 times a day for 7 days 
in conjunction with the probiotic  Saccharomyces cerevisiae (com-
monly referred to as  S. boulardii ) was selected. Symptoms 
promptly resolved upon antibiotic therapy. Four days after the 
end of treatment, the first recurrent CDAD episode occurred, 
which was successfully treated with antibiotic therapy of 125 mg 
vancomycin p.o. 4 times a day (q.i.d.) for 14 days. However, a 
second recurrence occurred 1 month after cessation of vancomy-
cin. Treatment with vancomycin was started again with a de-
creasing dosing scheme of 750 mg p.o. per day, 500 mg p.o. per 
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day and 375 mg p.o. per day for 1 week each followed by 125 mg 
p.o. q.i.d. every other day for 2 weeks and 125 mg p.o. q.i.d. every 
third day for another 3 weeks, as recommended  [10] . Two weeks 
after cessation of antibiotic therapy, a third CDAD episode oc-
curred. Again, therapy with vancomycin was initiated with an 
increased initial daily dose of 500 mg p.o. q.i.d. which was sub-
sequently decreased to 250 mg q.i.d.  [10] . During the treatment 
course, a vaginal  S. cerevisiae infection occurred, potentially re-
sulting from the previous use of the prebiotic containing this 
particular yeast. This infection was successfully treated with flu-
conazole. After a total of 6 weeks of vancomycin, the antibiotic 
regimen was changed to rifaximin 400 mg p.o. 2 times a day for 
14 days due to persisting symptoms  [39] . Eight weeks after ces-
sation of rifaximin therapy, a fourth CDAD episode emerged. A 
therapeutic trial with intravenous polyclonal immunoglobulins 
(Privigen ® ) 20 g given intravenously once was conducted with-
out a significant clinical response. At this time, colonoscopy re-
vealed no obvious abnormalities of the colonic and ileal muco-
sae, although an abnormal friability was observed.
 As standard treatment options remained unsuccessful, rescue 
treatment options were discussed between the clinicians and mi-
crobiologists. The recently published approach of a targeted ther-
apy with a monoclonal antibody against  C. difficile toxins  [40] was 
evaluated, but could not be performed as this drug was not yet 
available for clinical use.
 After discussion with the patient, FMT (also referred to as fecal 
bacteriotherapy) was performed with donor feces from the pa-
tient’s sister. Fresh donor feces (10 min after defecation) were pre-
pared by (1) resuspension of a cherry-sized amount of feces in 
120 ml of sterile 0.9% NaCl solution (B. Braun Melsungen AG, 
Melsungen, Germany), (2) two filtration steps through sterile 
gauze and (3) transferring 50 ml of the resulting bacterial suspen-
sion in each of two Entocort bottles (AstraZeneca) by intra-anal 
application. All preparation steps were performed in a laminar 
flow cabinet under biosafety level 2 conditions. Over the last 
2 months prior to FMT, the patient took vancomycin 125 mg q.i.d. 
p.o. The donor tested negative for HIV, HTLV, and hepatitis B and 
C infections, as well as negative for the presence of  C. difficile ,  Sal-
monella ,  Shigella ,  Campylobacter ,  Yersinia ,  Vibrio ,  Aeromonas and 
 Plesiomonas spp., and enteropathogenic  E. coli . The FMT proce-
dure was conducted within 30 min of preparation of the donor 
suspension by parallel application of the two bacteriotherapeutic 
enemas. The patient subsequently reported changes in the fre-
quency of bowel movements and intermittent obstipation, both of 
which ceased after 10 weeks. To date, the patient remains free of 
any symptoms (which has been roughly 3 years since FMT) and 
has reported significant amelioration of her general physical con-
dition. After FMT, the patient underwent two short antibiotic 
treatments, which did not cause any side effects.
 Results 
 Metagenomic Analysis of Intestinal Microbiome after 
FMT  
 FMT is a promising alternative to antibiotic treatment 
for recurrent CDAD  [14–37] . However, the nature of suc-
cessful FMT with respect to the microbial diversity in the 
recipient remains largely unknown. In accordance with 
our results, two recent studies have reported an increase 
in complexity and richness of patients’ intestinal micro-
biomes after FMT, employing 16S rRNA deep sequencing 
of recipients’ stool samples  [21, 29] . Metagenome analysis 
by deep sequencing is a powerful tool to assess the micro-
bial diversity of the gut  [41] , and has previously been 
widely applied to assess the composition and changes of 
the intestinal microbiota in health and disease, and as a 
consequence of environmental factors  [42] . To study the 
diversity of the intestinal microbiome of the patient pre-
sented here over time, we performed metagenomic deep 
sequencing of stool samples obtained at different time 
points from the recipient (the patient) and donor (the pa-
tient’s sister).
 To this end, we analyzed the donor stool sample at the 
time of FMT (donor, April 4, 2010; D0), as well as stool 
samples of the recipient 6–7 months after FMT in 2-week 
intervals (recipient, November 1, 2010, November 12, 
2010 and November 11, 2010; R1, R2 and R3). The re-
cipient’s sample at the time of FMT was unavailable due 
to inappropriate storage. DNA was isolated from about 
200 mg of frozen feces with the QIAamp DNA Stool Mini 
Kit (Qiagen), treated with DNase-free RNase (Fermen-
tas) and further purified by phenol-chloroform extrac-
tion. DNA was subjected to the illumina sequencing-by-
synthesis approach. Barcoded libraries were generated 
with 3–5 μg of DNA from each sample using the NEBnext 
DNA sample prep kit and were sequenced on a Genome 
Analyzer IIx in a 120-base-paired-end multiplex run. Se-
quencing yielded sets of 62,180,598–103,715,676 total 
reads ( table 1 ).
 The four read sets were assembled to contiguous se-
quences (contigs) with the CLC Genomics Workbench 
V5 (CLC bio). Standard parameters for read trimming 
and de novo assembly were used applying an increased 
similarity value of 0.9 and 80% read coverage to obtain 
draft genome sets of microorganisms present in the re-
spective samples. This yielded total contig lengths be-
tween 64,959 and 92,642 Mb ( table 1 ).
 Prokaryotic open reading frames (ORFs) of the indi-
vidual draft genomes were predicted with GLIMMER3 
 [43] , yielding sets ranging from 68,887 to 97,197 ORFs. 
The ORFs of each of the four samples were compared 
with BLASTP  [44] against the NRPROT protein database 
 [45] . About 80% of the ORFs of each of the four samples 
resulted in hits in NRPROT ( table 2 ).
 The first listed protein hit obtained by BLASTP com-
parison of each predicted ORF against NRPROT was an-
alyzed for taxonomical assignment with MEGAN  [46] . 
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LCA (‘last common ancestor’) parameters were adapted 
for deduced protein analysis by applying a minimal sup-
port of one, and deactivation of the low complexity filter. 
This approach only provides estimates of the abundance 
of individual microorganisms in the microbiome since 
those bacteria with larger numbers of genes are overrep-
resented. However, it provides an initial taxonomical 
 assignment and a statement about the presence or ab-
sence of microorganisms of interest, which in this case is 
 C. difficile . 
 Pie charts shown in  figure 1 a summarize the percent-
ages of deduced proteins assigned to phyla (major lineag-
es) of the Bacteria domain. Most proteins were consis-
tently assigned to the Firmicutes phylum in all of the four 
samples (68–73%), in accordance with previous studies of 
healthy intestinal microbiota  [41, 47, 48] . Interestingly, we 
also observed some differences between donor and recip-
ient. Proteins assigned to the Verrucomicrobia phylum, 
which has only been recently identified as constituent of 
the healthy intestinal microbiome  [49] , were detected in 
all three of the recipient’s samples (3–4% of the deduced 
protein pools), but were almost undetectable in the do-
nor’s sample ( fig. 1 b). This indicates an adaptation of the 
donor’s intestinal microbiome in the recipient intestinal 
tract following FMT. The composition of the recipient’s 
intestinal microbiome was stable over a time period of 1–6 
months after FMT, with only minor fluctuations ( fig. 1 a).
 The approach described here is suitable to detect intes-
tinal microorganisms up to the species level. In this case, 
it is of particular interest to determine the presence or 
absence of  C. difficile in the recipient’s intestine after 
FMT, as its absence would indicate successful treatment. 
Taxonomical assignment by MEGAN yielded only two 
significant hits to the  C. difficile species in the four sam-
ples, and only a minor proportion of the analyzed de-
duced proteins were assigned to a possible  C. difficile -re-
lated origin (species belonging to the Peptostreptococca-
ceae family). To further exclude the presence of  C. difficile , 
all ORFs that yielded hits to C. difficile in MEGAN were 
additionally inspected by BLASTX and BLASTN com-
parisons against NRPROT and GenBank, respectively. 
Those remaining ORFs yielding hits in this comparison 
were assigned to their respective contigs, which were ad-
ditionally inspected by BLASTX and BLASTN in the 
NCBI database. 
 One contig (No. 3183, 7,820 bp) of the R2 data set en-
codes a sigma-54-dependent transcriptional regulator 
(best hit in NRPROT WP_009903347; e-value 1e-144, 
38% identity), an amidohydrolase family protein 
(WP_003439599; e-value 0.0, 53% identity) and a renal 
dipeptidase family protein (best hit in NRPROT 
WP_003426730; e-value 0.0, 70% identity). The other 
contig was identified in the D0 data set (contig No. 16465, 
1,063 bp), which encodes a putative signaling protein 
(WP_003420236) of  C. difficile. These findings were in-
terpreted as rare exceptions and their origin still remains 
unclear because of the single occurrence.
 In addition to these analyses, all contigs of the four da-
tasets were screened for  rRNA operons showing similari-
ties to  C. difficile strain 630 (reference genome acc. No. 
NC_009089, position 10812–15968) and manually in-
spected. No hints for such an assignment were obtained, 
supporting the absence or rare presence of  C. difficile in 
all four samples.
 In contrast to 16S rRNA-based methods, the deep se-
quencing approach reported herein also allows the de-
tection of viruses. Consequently, we could detect about 
10 (8–11) types of bacteriophages in each of the four 
samples ( fig. 1 c), which might have been present as in-
tegrated prophages or free virus particles. In contrast, 
we found no hits to any potentially pathogenic eukary-
otic viruses. However, it should be noted that the ap-
proach relies on prokaryotic ORF prediction, and is thus 
biased towards prokaryotic virus (bacteriophage) detec-
tion. The number of proteins assigned to bacteriophag-
es compared with bacterial species was surprisingly low, 
Table 1.  Results obtained by illumina sequencing and subsequent 
assembly with the CLC Genomics Workbench V5 (CLC bio)
Sample Total reads, n Total contig 
length, Mb
Average (maximal) 
contig length, bp
D0 102,523,070 64,959 3,390 (305,461)
R1 103,715,676 68,167 4,533 (679,591)
R2 62,180,598 92,642 5,095 (678,885)
R3 101,830,352 69,314 3,991 (482,208)
Table 2.  ORF prediction and BLASTP analysis of deduced protein 
sequences
Sample Predicted 
ORFs
BLASTP against NRPROT, 
hits/no hits
D0 68,887 54,673/14,214
R1 69,997 56,352/13,645
R2 97,197 77,714/19,483
R3 72,235 57,469/14,766
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but is in accordance with reported findings  [50] . The 
reasons for that remain unknown and will require fur-
ther investigation.
 Discussion 
 Intestinal Microbiota and Microbiome 
 In recent years, substantial progress has been made in 
understanding the composition of the gut microbiota due 
to the availability of affordable high-throughput sequenc-
ing techniques  [51] . The discovery of numerous new bac-
terial species in the intestine  [41] and the increased un-
derstanding of the complexity of the human microbiome 
have changed the conception of the human microbiome: 
the importance of the entire microbial population and its 
complex composition (‘microbiota’) in conjunction with 
the associated genes (‘microbiome’) is increasingly recog-
nized as crucial for various aspects of health and disease. 
An estimated 100 trillion microorganisms (10 14 ) are pres-
ent in the human gastrointestinal tract  [52] , a quantity 10 
times greater than the estimated number of all eukary-
otic human cells per individual (10 13 ). The microbiota co-
evolved with the host and supplies indispensable func-
tions that humans cannot exert themselves, such as meta-
bolic properties  [53–56] or shaping of the adaptive and 
innate immune system  [57–59] .
 Fecal Transplantation for Recurrent CDAD 
 Administering foreign stool in an attempt to manipu-
late the composition of the human intestinal microbiota 
is not a new concept. The first description of FMT dates 
back to 1958. Eiseman et al.  [16] described the cases of 4 
patients with pseudomembranous enterocolitis that were 
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Chthoniobacter flavus
Verrucomicrobiae bacterium DG1235
Akkermansia muciniphila
Verrucomicrobium spinosum
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Opitutae
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Enterobacteria phage RB16
Enterobacteria phage RB43
Klebsiella phage KP15
Bacillus phage BCP78
Bacillus phage phi29
Bacteroides phage B124–14
Bacteroides phage B40–8
Clostridium phage phiCP34O
Lactococcus phage 936 sensu lato
Lactococcus phage phi41
Listeria phage 2389
Listeria phage B025
Rhodococcus phage ReqiPepy6
Sinorhizobium phage PBC5
Paramecium bursaria Chlorella virus 1
Clostridium phage phiSM101
Clostridium phage D-1873
Tetrasphaera phage TJE1
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Unclassified Siphoviridae
Unclassified Myoviridae
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dsDNA viruses, no RNA stage
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 Fig. 1. Taxonomical assignment of proteins identified in intestinal 
microbiota with MEGAN.  a Pie charts highlighting the BLASTP 
assignment of deduced proteins to bacterial phyla for the different 
samples.  b Taxonomical assignment of the Verrucomicrobia phy-
lum on the species level showing that these species were almost ex-
clusively detected in the recipient’s samples.  c Detection of viruses. 
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successfully treated with human enemas. Today, there are 
reports of more than 300 patients having undergone FMT 
for CDAD, mostly with impressive cure rates  [14–37] . A 
systematic review of studies for FMT against CDAD pub-
lished between 2000 and 2011 identified 124 patients of 
which 83% recovered immediately after the first FMT 
procedure  [22] . Another recent systematic review found 
that of 273 CDAD patients receiving FMT during the 
years 1946–2012, about 89% experienced clinical resolu-
tion  [32] . The successful FMT we report is in line with 
these previous reports.
 Deep Sequencing to Assess the Success of FMT 
 We treated a patient suffering from recurrent CDAD 
with feces donated by the patient’s sister after standard 
antibiotic therapy failed. The rationale for this approach 
has only recently been supplied when the human intesti-
nal microbiome was first deciphered and shown to be of 
high complexity, with several hundred different bacterial 
species residing in the intestine of each individual  [41, 
60] . This indicates that a healthy microbiota cannot eas-
ily be restored except by FMT from a healthy donor. This 
was largely unknown in most previous studies of FMT, 
but is now supported scientifically by increased under-
standing of the composition of the intestinal microbiota 
 [41, 42, 53, 60] . 
 We followed the FMT procedure by the only recently 
available metagenomic deep-sequencing technique, 
which provides a powerful tool to assess the microbial di-
versity residing in the human intestine  [41, 42, 53, 60] . 
Therefore, we employed the sequencing-by-synthesis ap-
proach to assess the intestinal microbial diversity of a pa-
tient with recurrent CDAD following FMT. We demon-
strated that a complex and diverse microbiome was estab-
lished in the patient employing a protocol that included 
de novo assembly of generated reads obtained from DNA 
of stool samples, prokaryotic ORF prediction, database 
alignment and taxonomical assignment. With this ap-
proach we could detect diverse and complex microbi-
omes predominated by Firmicutes in the donor as well as 
the recipient post-FMT. Furthermore, Verrucomicrobia 
species were identified only in the recipient’s samples, re-
flecting the flexibility of the intestinal microbiota and an 
adaptation to the new host’s intestinal microenviron-
ment. Most importantly, no indications for a  C. difficile 
infection were observed in any of the four samples, fur-
ther indicating successful treatment of CDAD. 
 The sequencing approach we report is suitable to de-
tect microorganisms up to the species level, which in con-
trast to 16S rRNA-based methods is also suitable to iden-
tify potentially pathogenic viruses. As reported herein, 
this approach may be used to exclude the presence of 
pathogens of interest, depending on the underlying dis-
ease and the patient’s and donor’s medical history.
 One major drawback, however, is that only limited 
quantitative conclusions can be drawn, as the analysis is 
based on genes and therefore does not necessarily repre-
sent an abundance of microorganisms. It should be noted 
that the three samples from the recipient which were an-
alyzed were obtained 6–7 months following FMT, and 
that unfortunately the recipient’s stool sample at the time 
of FMT was unavailable due to inappropriate storage 
conditions. We therefore could not compare the micro-
bial composition before and after FMT. However, the re-
cipient’s samples 6–7 months after successful FMT show 
a stable and diverse microbiome over a period of a month, 
predominated by Firmicutes, a hallmark of healthy intes-
tinal microbiota, and no indication of  C. difficile infec-
tion. Thus, the data indicates that a long-lasting reconsti-
tution of the intestinal microbiome was achieved in the 
patient, accompanied with cessation of clinical symp-
toms of CDAD. At the time of writing, the patient has 
been free of symptoms for 3 years.
 Recent studies applying 16S rRNA sequencing found 
that in CDAD patients who underwent successful FMT, 
a complex and diverse microbiome with highly abundant 
Firmicutes could be established  [18, 21, 29] . In accor-
dance with this, our study indicates that the donor’s as 
well as the recipient’s (post-FMT) intestinal microbiomes 
are mainly composed of Firmicutes ( fig. 1 a). In contrast, 
CDAD patients’ (including those after unsuccessful 
FMT) microbiomes are predominated by Proteobacteria 
species  [21] , which have been detected in relatively low 
abundance in the samples analyzed herein ( fig. 1 a).
 This is the first study to our knowledge to analyze in-
testinal microbiomes (metagenomes) of a patient with re-
current CDAD receiving FMT using the sequencing-by-
synthesis approach and taxonomical classification based 
on coding sequences obtained from de novo genome as-
semblies to follow the course of treatment over time. In 
accordance with the previous reports, the healthy donor’s 
as well as the recipient’s (after successful FMT) intestinal 
microbiomes showed comparable richness and composi-
tion of healthy individuals. The patient’s microbiome was 
of chimeric composition from donor and recipient.
 Despite the high and still growing number of serious 
 C. difficile infections worldwide  [7, 61] , the number of 
patients subjected to FMT is still small. This may be due 
to patients’ lack of knowledge and the fear of infections, 
as well as reluctance of physicians to a procedure that has 
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barely been systematically evaluated and approved by 
medical authorities  [62] . 
 In the majority of published cases (around 80%), FMT 
was performed during colonoscopy, but some delivery 
through a nasojejunal tube has been reported  [33] . For 
reasons of simplicity and security, we applied the fecal 
suspensions through intra-anal application. The instilla-
tion of a high bacterial load influences CDAD-associated 
dysbiosis via competitive mechanisms, consequently 
leading to a sustained favorable restoration of the intesti-
nal microbiota  [34] . Dysbiosis, defined as an altered com-
position of intestinal bacterial species, is a precondition 
that allows pathogenic  C. difficile to proliferate, ultimate-
ly causing overt infection  [63] . A beneficial effect of FMT 
with a more limited number of microorganisms has been 
successfully shown in a small case series with a mixture of 
10 facultative aerobic and anaerobic bacterial strains con-
tained in saline solution: a mixture that comprised  En-
terococcus ,  Clostridium ,  Bacteroides spp. and  E. coli  [35] .
 A first culture-independent investigation of the mi-
crobial composition before and after FMT by means of 
terminal restriction fragment length polymorphism and 
sequencing of 16S rRNA genes in one individual showed 
excellent concordance of microbial composition of the 
donor and recipient 14 days after FMT, whereas an ab-
normally low number of Firmicutes and Bacteroidetes was 
found in the gut microbiota of the recipient before trans-
plantation  [18] . We do not have any information about 
the abundance of Firmicutes in the recipient before FMT 
described here. The shift in intestinal microbial composi-
tion of a recipient induced by the transplantation proce-
dure was shown to be sustained at least over a period of 
24 weeks in a previous study  [34] . We show that a healthy 
and diverse microbiome was established in our patient 
6–7 months after FMT. The absence of CDAD symptoms 
in this patient for the last 3 years since the procedure sug-
gests that a healthy intestinal microbiome has been main-
tained.
 Concerns about transmission of bacterial, viral or par-
asitic pathogens, or even prions with donor stool, have 
been expressed. However, to the best of our knowledge, 
no case of such an infection in the course of FMT has been 
described to date. Approximately 3–15% of all humans 
are asymptomatic carriers of  C. difficile , with higher per-
centages in hospitalized patients  [64] . Therefore, donor 
stool should be checked for the presence of  C. difficile 
since transmission of spores or vital bacteria may hypo-
thetically hamper successful restoration of the recipient’s 
intestinal microbiota. Our analysis is suitable for that pur-
pose, and in comparison to 16S rRNA-based methods can 
identify viruses as well. However, the approach, as it relies 
on prokaryotic ORF prediction, is biased towards the 
identification of bacteriophages. Of note, bacteriophages 
have been shown to play important roles in the dynamics 
of the human intestinal microbiome in health and disease 
 [65] , and have been suggested to promote dysbiosis in in-
flammatory bowel disease  [66] . Due to their potential 
roles in intestinal disease and their putative use as bio-
markers, the need to include virome analyses in human 
microbiome projects has been expressed  [67] . As conven-
tional 16S rRNA-based metagenomic analyses cannot de-
tect bacteriophages, alternative approaches, as the one re-
ported here, are desired to include the virome, and could 
thus complement 16S rRNA-based methods.
 Additionally, the successful treatment of CDAD with 
FMT sheds light on other pathological conditions of the 
intestinal tract in which dysbiosis is considered a patho-
genic factor. For instance, FMT has been successfully em-
ployed to treat cases of inflammatory bowel disease, irri-
table bowel syndrome and constipation  [23, 68–70] .
 In conclusion, we have shown that a seriously ill pa-
tient can recover within a week after FMT from CDAD. 
The patient has been free of symptoms for a period of 
3 years with a significant increase in quality of life. In ad-
dition, FMT is a fast, simple, well-tolerated and even 
cheap procedure. 
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